Nicholas Schwab
Nicholas Schwab
University of Münster
Verified email at - Homepage
Cited by
Cited by
Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation
C Kleinschnitz, N Schwab, P Kraft, I Hagedorn, A Dreykluft, T Schwarz, ...
Blood 115 (18), 3835-3842, 2010
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
N Schwab, T Schneider-Hohendorf, V Posevitz, J Breuer, K Göbel, ...
Neurology 81 (10), 865-871, 2013
CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery
N Schwab, CG Bien, A Waschbisch, A Becker, GH Vince, K Dornmair, ...
Brain 132 (5), 1236-1246, 2009
Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity
J Breuer, N Schwab, T Schneider‐Hohendorf, M Marziniak, H Mohan, ...
Annals of neurology 75 (5), 739-758, 2014
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells
T Schneider-Hohendorf, J Rossaint, H Mohan, D Böning, J Breuer, ...
Journal of Experimental Medicine 211 (9), 1833-1846, 2014
Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control
N Schwab, JC Ulzheimer, RJ Fox, T Schneider-Hohendorf, BC Kieseier, ...
Neurology 78 (7), 458-467, 2012
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation
CC Gross, A Schulte-Mecklenbeck, A Rünzi, T Kuhlmann, ...
Proceedings of the National Academy of Sciences 113 (21), E2973-E2982, 2016
T cell suppression by naturally occurring HLA‐G‐expressing regulatory CD4+ T cells is IL‐10‐dependent and reversible
YH Huang, AL Zozulya, C Weidenfeller, N Schwab, H Wiendl
Journal of leukocyte biology 86 (2), 273-281, 2009
Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification
N Schwab, T Schneider-Hohendorf, N Melzer, G Cutter, H Wiendl
Neurology 88 (12), 1197-1205, 2017
CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy
T Schneider-Hohendorf, N Schwab, N Üçeyler, K Göbel, C Sommer, ...
Neurology 78 (6), 402-408, 2012
An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis
N Schwab, AL Zozulya, BC Kieseier, KV Toyka, H Wiendl
The Journal of Immunology 184 (9), 5368-5374, 2010
Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis
T Schneider‐Hohendorf, MP Stenner, C Weidenfeller, AL Zozulya, ...
European journal of immunology 40 (12), 3581-3590, 2010
PML risk stratification using anti-JCV antibody index and L-selectin
N Schwab, T Schneider-Hohendorf, B Pignolet, M Spadaro, D Görlich, ...
Multiple Sclerosis Journal 22 (8), 1048-1060, 2016
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
N Schwab, T Schneider-Hohendorf, B Pignolet, J Breuer, CC Gross, ...
Neurology-Neuroimmunology Neuroinflammation 3 (1), 2016
CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing
T Schneider-Hohendorf, H Mohan, CG Bien, J Breuer, A Becker, D Görlich, ...
Nature communications 7 (1), 1-14, 2016
FOXP3+ T regulatory cells in idiopathic inflammatory myopathies
A Waschbisch, N Schwab, T Ruck, MP Stenner, H Wiendl
Journal of neuroimmunology 225 (1-2), 137-142, 2010
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis
N Schwab, T Schneider-Hohendorf, H Wiendl
International immunology 27 (1), 47-53, 2015
Immunological and clinical consequences of treating a patient with natalizumab
N Schwab, KG Höhn, T Schneider-Hohendorf, I Metz, MP Stenner, S Jilek, ...
Multiple Sclerosis Journal 18 (3), 335-344, 2012
Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants
A Kroner, N Schwab, CW Ip, S Ortler, K Göbel, KA Nave, M Mäurer, ...
The American journal of pathology 174 (6), 2290-2299, 2009
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment
L Klotz, J Havla, N Schwab, R Hohlfeld, M Barnett, S Reddel, H Wiendl
Therapeutic advances in neurological disorders 12, 1756286419836571, 2019
The system can't perform the operation now. Try again later.
Articles 1–20